Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 10

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 10
---
 Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should
not be relied on as accurately representing the current state of our affairs.

Unless the context specifically
indicates otherwise, references in this prospectus to “Biodexa Pharmaceuticals PLC,” “Biodexa,” “the Company,”
“we,” “our,” “ours,” “us,” “the Group,” or similar terms refer to Biodexa
Pharmaceuticals plc and its consolidated subsidiaries.

For investors outside the United States: We have not, and the placement agent has not, taken any action to permit this offering, or to permit the possession or distribution of this prospectus, in any jurisdiction where action for that purpose is required, other than the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to the offering of the Depositary Shares and the distribution of this prospectus outside of the United States.

| 1 |

<div align='center'>PRESENTATION OF FINANCIAL AND OTHER INFORMATION</div>

Our financial statements are
prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board and
adopted by the European Union. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical
figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.

We prepare our consolidated
financial statements in British pounds sterling. Except as otherwise stated, all monetary amounts in this prospectus are presented in
British pounds sterling.

In this prospectus, unless
otherwise specified or the context otherwise requires:

| · | “$” and “U.S. dollar” each refer to the United States dollar (or units thereof); 
 and                                                                              |

| · | “£,” “pence” and “p” each refer to the British pound sterling 
 (or units thereof).                                           |

On March 27, 2023, following
shareholder approval at a general meeting, we effected a one-for-20 reverse stock split of our Ordinary Shares, and our consolidated Ordinary
Shares began trading on AIM, a market operated by the London Stock Exchange plc, or AIM, on a split-adjusted basis as of such date. No
fractional shares were issued in connection with the reverse stock split. At the same general meeting, our shareholders approved the cancellation
of admission